Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Takeda Pharmaceutical Co ( (JP:4502) ) has issued an announcement.
Takeda Pharmaceutical announced that Julie Kim, currently the president of its U.S. Business Unit, will succeed Christophe Weber as CEO in June 2026. This decision follows a multi-year succession process by the Board of Directors. Under Weber’s leadership, Takeda transformed into a competitive global biopharmaceutical entity with a strong R&D focus. Kim’s leadership is expected to continue building on the company’s success, promoting its values and expanding its impact on patients worldwide.
More about Takeda Pharmaceutical Co
Takeda Pharmaceutical Co is a leading R&D-driven biopharmaceutical company headquartered in Japan. The company focuses on discovering and delivering life-transforming treatments in therapeutic areas such as gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience, and vaccines. With operations in approximately 80 countries, Takeda is committed to improving patient experiences and advancing treatment options through its dynamic and diverse pipeline.
YTD Price Performance: -2.61%
Average Trading Volume: 17,247
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $42.73B
For a thorough assessment of 4502 stock, go to TipRanks’ Stock Analysis page.
